BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22213031)

  • 1. KIT protein expression and mutational status of KIT gene in pituitary adenomas.
    Casar-Borota O; Fougner SL; Bollerslev J; Nesland JM
    Virchows Arch; 2012 Feb; 460(2):171-81. PubMed ID: 22213031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of c-kit (CD117) expression in human normal pituitary cells and pituitary adenomas.
    La Rosa S; Uccella S; Dainese L; Marchet S; Placidi C; Vigetti D; Capella C
    Endocr Pathol; 2008; 19(2):104-11. PubMed ID: 18568298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 gene mutations in pituitary adenomas: rare events.
    Levy A; Hall L; Yeudall WA; Lightman SL
    Clin Endocrinol (Oxf); 1994 Dec; 41(6):809-14. PubMed ID: 7889618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.
    Knösel T; Chen Y; Altendorf-Hofmann A; Danielczok C; Freesmeyer M; Settmacher U; Wurst C; Schulz S; Yang LL; Petersen I
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):397-403. PubMed ID: 22160160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific analysis of KIT and PDGFR-alpha expression and mutational status in Merkel cell carcinoma.
    Swick BL; Srikantha R; Messingham KN
    J Cutan Pathol; 2013 Jul; 40(7):623-30. PubMed ID: 23621836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations and protein expression of KIT and PDGFRA genes in ipsilateral testicular seminomas: an immunohistochemical and molecular genetic study.
    Terada T
    Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):450-3. PubMed ID: 21403518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immunohistochemical and molecular genetic analysis of KIT and PDGFRA in small cell lung carcinoma in Japanese.
    Terada T
    Int J Clin Exp Pathol; 2012; 5(4):331-8. PubMed ID: 22670177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
    Debiec-Rychter M; Dumez H; Judson I; Wasag B; Verweij J; Brown M; Dimitrijevic S; Sciot R; Stul M; Vranck H; Scurr M; Hagemeijer A; van Glabbeke M; van Oosterom AT;
    Eur J Cancer; 2004 Mar; 40(5):689-95. PubMed ID: 15010069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours.
    Vax VV; Bibi R; Diaz-Cano S; Gueorguiev M; Kola B; Borboli N; Bressac-de Paillerets B; Walker GJ; Dedov II; Grossman AB; Korbonits M
    J Endocrinol; 2003 Aug; 178(2):301-10. PubMed ID: 12904177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the Notch3 receptor in non-functioning pituitary tumours.
    Miao Z; Miao Y; Lin Y; Lu X
    J Clin Neurosci; 2012 Jan; 19(1):107-10. PubMed ID: 22153798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
    Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Gs alpha mutations in Korean patients with pituitary adenomas.
    Kim HJ; Kim MS; Park YJ; Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Jung HW; Han DH; Lee HS; Chi JG
    J Endocrinol; 2001 Feb; 168(2):221-6. PubMed ID: 11182759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
    Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
    Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of beta-catenin mutations and alpha-, beta-, and gamma-catenin expression in normal and neoplastic human pituitary tissues.
    Tziortzioti V; Ruebel KH; Kuroki T; Jin L; Scheithauer BW; Lloyd RV
    Endocr Pathol; 2001; 12(2):125-36. PubMed ID: 11579678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-KIT Analysis and Targeted Molecular Sequencing of Mesonephric Carcinomas of the Female Genital Tract.
    Pors J; Ho J; Prentice L; Thompson E; Cochrane D; Gibbard E; Huntsman D; Gilks B; Hoang LN
    Am J Surg Pathol; 2020 Apr; 44(4):495-502. PubMed ID: 31714258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
    Holtkamp N; Okuducu AF; Mucha J; Afanasieva A; Hartmann C; Atallah I; Estevez-Schwarz L; Mawrin C; Friedrich RE; Mautner VF; von Deimling A
    Carcinogenesis; 2006 Mar; 27(3):664-71. PubMed ID: 16357008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas.
    Petersenn S; Heyens M; Lüdecke DK; Beil FU; Schulte HM
    Clin Endocrinol (Oxf); 2000 Jan; 52(1):35-42. PubMed ID: 10651751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas.
    Morita K; Takano K; Yasufuku-Takano J; Yamada S; Teramoto A; Takei M; Osamura RY; Sano T; Fujita T
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):435-41. PubMed ID: 18070145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
    Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
    Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.